The Invenomic US Equity Long/Short UCITS Fund (the “Fund”) is a diversified, all-cap US equity long/short strategy based on fundamental analysis managed by Invenomic Capital Management, L.P. (“Invenomic”).

Invenomic was founded in 2015 by Ali Motamed.  Over the last 15 years, Mr. Motamed has developed and managed what has become the Invenomic strategy.  The strategy employs a value-biased, sector agnostic and long/short approach, investing in all-cap equities predominantly within North America. 

The objective of the Fund is to achieve long-term capital appreciation. To achieve this, the Invenomic strategy adopts 3 core principles: 1) investing in fundamentally sound companies 2) disciplined short selling and 3) diversification – an essential risk management tool.

Portfolio construction is based on an intensive investment process leveraging quantitative screens on the front end and fundamental analysis on the back end.  A diversified short portfolio is composed of individual equities that are intended to generate positive returns.  The strategy utilises variable net exposures, with an expected average net between 40%-60% but that may be as low as 0% and as high as 80% in extreme market environments. Invenomic’s net exposure is completely derived by security selection and is not intended to be a market timing tool.  Gross exposure will generally be between 130%-200%.


Invenomic US Equity Long/Short UCITS Fund


Investing in companies with strong fundamentals with a core focus on sustainable free cash flow generation, consistent earnings histories, and sensible capital deployment.


Disciplined Short Selling - concentrating on concept stocks, deteriorating businesses and inflated valuations based on unsustainable events.


Diversification: An essential risk management tool that allows the firm to access multiple opportunities across the spectrum of the market. 


Manager pedigree, ex-Boston Partners and Morningstar L/S Manager of the Year in 2014.

Terms and Conditions Apply

Read the disclaimer

Waystone Investment Management (IE) Limited, 23 St. Stephen's Green, Dublin 2, D02 AR55, Ireland is licensed to provide Investment Management services to Professional Clients (including Collective Investment Schemes) by the Central Bank of Ireland.

MontLake UCITS Platform ICAV is an umbrella open-ended Irish collective asset-management vehicle with segregated liability between Funds formed in Ireland under the Irish Collective Asset-management Vehicles Act 2015 and authorised by the Central Bank as a UCITS pursuant to the UCITS Regulations.

The Manager of MontLake UCITS Platform ICAV is Waystone Fund Management (IE) Limited, a company regulated by the Central Bank of Ireland. 

This website is directed mainly for professional and institutional clients who possess the necessary experience, knowledge and expertise to make their own investment decisions and properly assess the risk that it incurs.

Information on this website was obtained from various sources and the company does not guarantee its accuracy. The information is for your private use and discussion purposes only and expressed views and opinions may change.

The Performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. The value of your investment and their income may go down as well as up.

Your investment may also be subject to currency, interest rate, as well as market fluctuations. Consequently the Investor may not get back a sum equal to that he / she originally invested.

Investors should note that an investment in those Sub-Funds which may invest in emerging markets should not constitute a substantial proportion of an investment portfolio and may not be appropriate for all investors.

The Sub-Funds may invest in Over the Counter as well as Exchange Traded derivative instruments to enhance return or hedge against fluctuations in security prices or market rates as well as to short sell a security through the use of a derivative instrument. Transactions in derivative instruments involve a risk of loss or depreciation of capital due to adverse changes in security prices, exchange rates or interest rates or in the case of OTC instruments default of Counterparty. This investment may not be suitable for all types of investors. It is therefore recommended that you consult your investment advisor.

A commission or sales fee may be charged at the time of the initial purchase for an investment and may be deducted from the invested amount therefore lowering the size of your investment. The Investment Manager will be entitled to receive a performance fee as well as a management fee, calculated on a daily basis and paid quarterly by the sub-funds.

The Levels and bases of taxation are dependent on individual circumstances and subject to change and therefore it is highly recommended that you consult a professional tax advisor.